Chong B, Kong G, Shankar K, Chew HSJ, Lin C, Goh R, et al. The global syndemic of metabolic diseases in the young adult population: a consortium of trends and projections from the Global Burden of Disease 2000–2019. Metabolism. 2023;141:155402. https://doi.org/10.1016/j.metabol.2023.155402.

Article  CAS  PubMed  Google Scholar 

Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. 2023;35:414–28.e3. https://doi.org/10.1016/j.cmet.2023.02.003.

Article  CAS  PubMed  Google Scholar 

Organisation WH. Obesity and overweight fact sheet. World Health Organisation. Accessed 01/05/2022, 2022. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight.

Kinlen D, Cody D, O’Shea D. Complications of obesity. QJM. 2018;111:437–43. https://doi.org/10.1093/qjmed/hcx152.

Article  CAS  PubMed  Google Scholar 

Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1–203. https://doi.org/10.4158/EP161365.GL.

Article  PubMed  Google Scholar 

Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—what the non-specialist needs to know. Diabetes Obes Metab. 2022;24:3–14. https://doi.org/10.1111/dom.14521.

Article  PubMed  Google Scholar 

Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive review and updates on holistic approach towards non-alcoholic fatty liver disease management with cardiovascular disease. Curr Atheroscler Rep. 2022; https://doi.org/10.1007/s11883-022-01027-5.

Avila C, Holloway AC, Hahn MK, Morrison KM, Restivo M, Anglin R, et al. An overview of links between obesity and mental health. Curr Obes Rep. 2015;4:303–10.

Article  PubMed  Google Scholar 

Nyberg ST, Batty GD, Pentti J, Virtanen M, Alfredsson L, Fransson EI, et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. Lancet Public Health. 2018;3:e490–7.

Article  PubMed  PubMed Central  Google Scholar 

Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.

Article  PubMed  PubMed Central  Google Scholar 

de la Iglesia R, Loria-Kohen V, Zulet MA, Martinez JA, Reglero G, de Molina AR. Dietary strategies implicated in the prevention and treatment of metabolic syndrome. Int J Mol Sci. 2016;17. https://doi.org/10.3390/ijms17111877.

Lin C, Yeong TJJ, Lim WH, Ng CH, Chun EY, Chin YH, et al. Comparison of mechanistic pathways of bariatric surgery in patients with diabetes mellitus: a Bayesian network meta-analysis. Obesity (Silver Spring). 2022;30:1380–90. https://doi.org/10.1002/oby.23453.

Article  CAS  PubMed  Google Scholar 

Frías JP, Davies MJ, Rosenstock J, Manghi FCP, Lando LF, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov’t. N Engl J Med. 2021;385:503–15. https://doi.org/10.1056/NEJMoa2107519.

Article  PubMed  Google Scholar 

Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65:1251–61. https://doi.org/10.1007/s00125-022-05715-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II/III trials. Pharmaceuticals (Basel, Switzerland). 2021;14. https://doi.org/10.3390/ph14100991.

Jung HN, Jung CH. The upcoming weekly tides (Semaglutide vs. Tirzepatide) against obesity: STEP or SURPASS? Review. J Obes Metab Syndr. 2022;31:28–36. https://doi.org/10.7570/JOMES22012.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar 

Kolkailah AA, Doukky R, Pelletier MP, Volgman AS, Kaneko T, Nabhan AF. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk. Cochrane Database Syst Rev. 2019;12:Cd013319. https://doi.org/10.1002/14651858.CD013319.pub2.

Article  PubMed  Google Scholar 

Liao YB, Li YJ, Jun-Li L, Zhao ZG, Wei X, Tsauo JY, et al. Incidence, predictors and outcome of prosthesis-patient mismatch after transcatheter aortic valve replacement: a systematic review and meta-analysis. Sci Rep. 2017;7:15014. https://doi.org/10.1038/s41598-017-15396-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63. https://doi.org/10.1016/S0140-6736(03)15268-3.

Article  Google Scholar 

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135.

Article  PubMed  PubMed Central  Google Scholar 

Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–13. https://doi.org/10.2307/2331986.

Article  Google Scholar 

Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rucker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10:476–83. https://doi.org/10.1002/jrsm.1348.

Article  PubMed  PubMed Central  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2.

Article  CAS  PubMed  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–60. https://doi.org/10.1136/bmj.327.7414.557.

Article  PubMed  PubMed Central  Google Scholar 

Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. 2008:243–96. https://training.cochrane.org/handbook/current/chapter-10.

Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis With R: A Hands-On Guide. 1st ed. Chapman & Hall/CRC Press; 2021.

Collaboration TC. Recommendations on testing for funnel plot asymmetry. Accessed 17 August 2022, 2022. https://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm.

Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. Journal: Article in Press. N Engl J Med. 2022; https://doi.org/10.1056/NEJMoa2206038.

Ludvik B, Giorgino F, Jodar E, Frias JP, Lando LF.Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London, England). 2021;398:583–98. https://doi.org/10.1016/S0140-6736(21)01443-4. Comment in: Lancet. 2021; 398:560–561. PMID: 34370968 https://www.ncbi.nlm.nih.gov/pubmed/34370968.

Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Journal Article; Clinical Trial Protocol. Lancet. 2021;398:1811–24. https://doi.org/10.1016/S0140-6736(21)02188-7.

Article  PubMed  Google Scholar 

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. https://doi.org/10.1016/j.molmet.2018.09.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocr. 2022;10:634–44. https://doi.org/10.1016/s2213-8587(22)00187-5.

Article  CAS  Google Scholar 

Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov’t. Lancet Diabetes Endocrinol. 2022;10:418–29. https://doi.org/10.1016/S2213-8587(22)00085-7.

Article  CAS  PubMed  Google Scholar 

O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637–49. https://doi.org/10.1016/S0140-6736(18)31773-2.

Article  PubMed  Google Scholar 

Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Rev Diabetes Ther. 2021;12:143–57. https://doi.org/10.1007/s13300-020-00981-0.

Article  CAS  Google Scholar 

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180–93. https://doi.org/10.1016/s0140-6736(18)32260-8.

Article  CAS  PubMed  Google Scholar 

Chin YH, Ng CH, Chew NW, Kong G, Lim WH, Tan DJH, et al. The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis. EClinicalMedicine. 2022;54:101685. https://doi.org/10.1016/j.eclinm.2022.101685.

Article  PubMed  PubMed Central  Google Scholar 

Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17. https://doi.org/10.1007/978-3-319-48382-5_1.

Article  CAS  PubMed  Google Scholar 

Muthiah M, Ng CH, Chan KE, Fu CE, Lim WH, Tan DJH, et al. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Ann Hepatol. 2023;28:100762. https://doi.org/10.1016/j.aohep.2022.100762.

Article  CAS  PubMed